Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

IntraCellular Therapies describes new norepirephrine/serotonin transporter inhibitors

Feb. 27, 2009

Cerimon initiates enrollment into phase III clinical studies of diclofenac sodium patch

Feb. 26, 2009

Winston receives orphan drug designation for novel postherpetic neuralgia patch

Feb. 26, 2009

Valdoxan approved for the treatment of major depressive episodes in Europe

Feb. 26, 2009

Insulin signaling, a potential target for Alzheimer's disease

Feb. 26, 2009

New norepinephrine, 5-HT and dopamine reuptake inhibitors in development at DOV

Feb. 26, 2009

NeuroSearch reports phase II proof-of-concept results for NS-2359 in depression

Feb. 25, 2009

Ambrx and Merck Serono sign agreement to develop and commercialize ARX-424 for MS

Feb. 25, 2009

Primary objective of STRIDE-PD Stalevo study was not achieved

Feb. 25, 2009

GW reports encouraging results in randomized withdrawal Sativex study

Feb. 25, 2009

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 13, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
GWAS identifies variant associated with diabetic retinopathy and susceptibility to T2D
BioWorld Science
Scientists at the University of Nottingham Ningbo China and collaborators aimed to identify genetic variants associated with diabetic retinopathy.